Drugs / NEO6860
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02337543 | Jan → Jul 2015 | osteoarthritis, knee | Neomed Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02712957 | Mar → Nov 2016 | osteoarthritis, knee | Neomed Institute | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEO6860 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02712957 ↗ |
| Action | Inhibit | “NEO6860 is a TRPV1 antagonist, blocking capsaicin activation of the target” PMID 28188907 ↗ Feb 2017 |
| Modality | Small molecule | “NEO6860 is an NCE acting as a TRPV1 antagonist” NCT02337543 ↗ |
| Route | Oral | “single and multiple oral dose” NCT02337543 ↗ |
| Target | TRPV1 | “NEO6860 is a TRPV1 antagonist, blocking capsaicin activation of the target” PMID 28188907 ↗ Feb 2017 |